Page 1

Richter publishes Q2 / H1 2026 results 07/08/2026 Improving dynamics and upgraded Clean EBIT guidance CER Pharma revenues grew by 8.7 % , driven by CNS and BIO and also reflecting improving WHC and GenMed dynamics in Q2 . Reported Pharma revenues declined by 0.5 % YoY to HUF 455bn in H1 2026 , implying around 9ppt currency headwind . CER Clean EBIT ( pharma ) growth was outstanding at 21 % , driven by the outperformance of cariprazine and the benefits of our multi - year efficiency initiatives ; reported Clean EBIT ( pharma ) grew by only 3 % to HUF 151.8bn . Net profit was HUF 103.5bn in H1 2026 , down by 14 % YoY due to large , HUF 27.1bn FX losses burdening the period . Free Cash Flow generation was up by a solid 24 % YoY to HUF 137bn . 2026 Clean EBIT guidance ( at constant exchange rates , CER ) is upgraded to " double - digit growth " on the back of the strong H1 profitability . Budapest , 7 August 2026 - Gedeon Richter Plc . ( " Richter ” ) announced today its Q2 / H1 2026 financial results . CER ( constant exchange rate ) Pharma revenues grew by 8.7 % in H1 2026 , in line with the high - single - digit growth guidance for the full year and reflected improving dynamics in Q2 . FX remains a major drag on reported revenues and represented around 9ppt headwind in H1 ( primarily due to the strong HUF ) . Hence , reported Pharma revenues declined by 0.5 % YoY to HUF 455bn in H1 2026 . CNS revenues increased by 7 % in H1 2026 YoY , as currency movements partly offset the impressive performance of VraylarⓇ ( AbbVie's net sales increased by 19 % YoY to USD 1.98bn reflecting strong demand growth and market share gains in both bipolar disorder and adjunctive MDD ) and jumping Reagila® sales ( + 25 % CER , driven by higher supply revenues and high- performing countries in both Richter and partner territories ) . Women's Healthcare sales growth ( + 7 % CER in H1 ) accelerated in Q2 as Endometriosis and Menopause consistently outperform expectations . Lower Eastern European sales and slower dynamics in traditional OC products continue to affect top- line growth . The underlying strength of the leading products ( Drovelis® , Ryeqo® , Lenzetto® and Bemfola® ) remains intact . BIO revenues jumped in H1 ( + 30 % CER ) , driven by biosimilar revenues ( very strong teriparatide sales and new product launches ) . GenMed revenues fell by 5 % in H1 YoY ( CER ) although sales dynamics have incrementally been improving . The lack of flu season ( weak OTC ) , a high base and the ongoing rationalization of distributors ' inventory holding affected top - line . Gross profit ( pharma ) fell by 2.2 % YoY to HUF 314bn in H1 2026 ; gross margin declined to 69 % ( -1.2ppt ) , despite improving trends in Q2 . CER Clean EBIT ( pharma ) growth was outstanding at 21 % in H1 2026 , driven by the outperformance of cariprazine , improving WHC profitability and also supported by lower opex . Reported Clean EBIT ( pharma ) grew by only 3 % to HUF 151.8bn due to the FX headwind . Reported EBIT stood at HUF 143.5bn in H1 2026 , 2.2 % higher YoY . Net profit ( attributable to the owners of the parent ) was HUF 103.5bn in H1 2026 , declining by 14 % YoY , as a result of large , HUF 27.1bn FX losses ( mostly unrealized yet ) burdening the period as financial expenses .